Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

Sponsor
Yehui Tan
Study ID
NCT07023588
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Acute Myeloid Leukemia (AML)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Venetoclax — DRUG
    Patients identified with a suboptimal response to chemotherapy based on minimal residual disease (MRD) levels in peripheral blood on Day 6 will initiate venetoclax therapy added on Day 8, administered for 7 days.

Study Details

A multicenter, open-label, prospective, randomized controlled study to optimize the treatment of patients with acute myeloid leukemia based on early peripheral blood minimal residual disease

Key Dates

Start date
Jun 1, 2025
Status verified
Aug 2025
Primary completion
May 31, 2029
Completion
May 31, 2029

Study Design

Enrollment
70 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: venetoclax，8-14d
  • No Intervention: Control group

Primary Outcome Measure

Modified Composite Complete Response Rate（mCRc） [ Time Frame: Through study completion, an average of 1 year ]

Central Contacts

Related Studies